Editorial: The role of omics characteristics in the diagnosis, treatment, and prognosis of autoimmune diseases

Front Immunol. 2022 Nov 2:13:1069918. doi: 10.3389/fimmu.2022.1069918. eCollection 2022.

Qinglong Wu¹, Kang Ning², Xiaoxiao Zhao³, Feng Liao³, Min Wang^{3

4}, Longgang Chang³, Yanmin Liu⁴, Jinmiao Chen^{5

6}, Ming Zhao⁷, Zhangran Chen^{3

4

8}

¹ Texas Children's Microbiome Center, Baylor College of Medicine, Houston, TX, United States.
² School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
³ Shenzhen Wedge Microbiology Research Co.Ltd, Shenzhen, China.
⁴ Inner Mongolia Shuangqi Pharmaceutical Co.Ltd, Huhhot, China.
⁵ Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.
⁶ Immunology Translational Research Program, Yong Loo Lin School of Medicine, Department of Microbiology and Immunology, National University of Singapore (NUS), Singapore, Singapore.
⁷ The Second Xiangya Hospital, Central South University, Changsha, China.
⁸ Department of Gastroenterology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, China.

No abstract available

Keywords: autoimmune diseases; biomarker; fecal microbiota; microRNAs; omics technology; rheumatoid arthritis.

Publication types